Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Cognitive dysfunction

NMDAR

In vitro and mouse studies suggest 24(S) hydroxycholesterol (24(S)-HC) could help treat cognitive dysfunction. In screening studies using patch-clamp recordings on mouse hippocampal neurons, 24(S)-HC was selected from a panel of sterol-based compounds as a potent submicromolar potentiator of NMDAR-mediated currents. In mouse hippocampal slices, 24(S)-HC produced long-term potentiation (LTP) from a subthreshold tetanus stimulus and reversed NMDAR antagonist-induced LTP suppression. In behavioral memory tests in mice, a 24(S)-HC analog reversed NMDAR agonist suppression of memory-dependent activity. Next steps are being performed by Sage Therapeutics Inc. and include optimizing 24(S)-HC analogs in models of schizophrenia.

SciBX 6(48); doi:10.1038/scibx.2013.1395
Published online Dec. 19, 2013

Patent application filed by Sage Therapeutics; licensing information available from Sage Therapeutics
Contact: Jeff Jonas, Sage Therapeutics Inc., Cambridge, Mass.
e-mail:
jeff@sagerx.com

Paul, S.M. et al. J. Neurosci.;
published online Oct. 30, 2013;
doi:10.1523/JNEUROSCI.2619-13.2013
Contact: Steven M. Paul, Weill Cornell Medical College, New York, N.Y.
e-mail:
smpaulmd@med.cornell.edu